Healthcare

Report by Inferential Focus

The potential of using psychedelics for therapeutic benefit has taken several steps forward recently. The FDA is getting closer to issuing specific guidance and guidelines for the use of psychedelic drugs to treat mental illnesses - notably for depression and PTSD - as well as for addictions and for use in clinical trials. Psychedelics are gaining cultural awareness and acceptance, with two US states (Oregon and Colorado) legalising controlled uses. Investors are taking notice. By last year, more than 50 psychedelics companies, including Compass Pathways and ATAI Life Sciences, had gone public at a combined valuation of over $2bn.